Fig. 6

TO901317 reduced neutrophil infiltration and microglial activation but had no effect on MMP-9 activity. Representative a MPO-stained, b Iba-1-stained, and c CD45-stained brain sections from sham-injured, vehicle-treated, and 30 mg/kg TO901317-treated mice at 4, 7 and 14 days post-ICH. Cell count analysis shows that TO901317-treated mice had significantly fewer MPO-positive, total Iba-1-positive, activated Iba-1-positive, and CD45-positive cells than vehicle-treated mice in the peri-hematoma area at 4 and 7 days post-ICH. The number of MPO-positive, Iba-1-positive, and CD45 positive cells is expressed as the mean number per field of view (0.8 mm²). The scale bar is 100 μm. d Representative zymography of MMP-9 activity from a sham-injured control, a vehicle-treated, and a 30 mg/kg TO901317-treated mouse at 1 day post-ICH. There was no difference in MMP-9 activity between vehicle-treated and TO901317-treated mice. Values are mean ± SEM; ^* P < 0.05 versus sham group, ^# P < 0.05, ^## P < 0.01, and ^### P < 0.001 versus vehicle group (n = 6–7 mice/group, Student’s t test for MPO, Iba-1, and CD45 immunohistochemistry; n = 6 mice/group, one-way ANOVA for MMP-9 zymography)